Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
0.8490
-0.0494 (-5.50%)
Apr 10, 2026, 4:00 PM EDT - Market closed
Werewolf Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
39
Market Cap
41.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.89M | -18.06M | -90.55% |
| Dec 31, 2023 | 19.94M | 3.54M | 21.60% |
| Dec 31, 2022 | 16.40M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionHOWL News
- 16 days ago - Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 6 weeks ago - Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives - GlobeNewsWire
- 4 months ago - Werewolf Therapeutics Announces Pipeline and Business Updates - GlobeNewsWire
- 5 months ago - Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting - GlobeNewsWire
- 5 months ago - Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer - GlobeNewsWire
- 6 months ago - Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting - GlobeNewsWire
- 7 months ago - Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire